Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P230013/S029

Edwards EVOQUE Tricuspid Valve Replacement System

Edwards Lifesciences, LLC · Decision date Oct 19, 2026

MEDTECHLEDGER EXPLANATIONP230013/S029

What did the FDA approve?

The FDA record for P230013/S029, dated 2026-10-19, describes an approved update to specifications for the Coated Capsule used with the Edwards EVOQUE Tricuspid Valve Replacement System. As stated, the change permits signs of delamination on the inner diameter of the proximal weld ring. The supplement is filed under the 135 review track for 30-day notice with reason listed as a process change involving a manufacturer, sterilizer, packager or supplier.

The identifier P230013 links this action to the original PMA of that number, and the S029 suffix indicates a supplement rather than a new approval of the whole system. The record does not specify the visual acceptance criteria, test methods, or limits applied to the delamination signs, nor does the stated purpose constitute independent evidence of safety or clinical effectiveness.

FDA approval order statement

Approval for updated specifications for the Coated Capsule to allow signs of delamination on the inner diameter of the proximal weld ring.
Regulatory pathway
PMA supplement
Supplement type
135 Review Track For 30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 19, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P230013/S029
Regulatory pathway
PMA supplement
Product code
NPW
Decision code
APPR
Decision date
Oct 19, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneously Delivered Prostheses and Tricuspid Valves.

Product code
NPW
FDA device class
3

For the original device and its historical approval scope, see PMA P230013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P230013 · Original PMA

    Edwards EVOQUE Tricuspid Valve Replacement System

  2. P230013/S029 received

    Application receipt date recorded by FDA.

  3. P230013/S027 · Related supplement

    EVOQUE Tricuspid Valve Replacement System

  4. P230013/S029 · FDA decision

    135 Review Track For 30-Day Notice

  5. P230013/S033 · Related supplement

    EVOQUE Tricuspid Valve Replacement System

  6. P230013/S034 · Related supplement

    Edwards EVOQUE Tricuspid Valve Replacement System (9850EV)

Timeline entries are records held by MedtechLedger for P230013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P230013

Product / regulatory recordCompanyPathwayDecision dateSource
Edwards Lifesciences, LLCPMA approvalFeb 1, 2024FDA
Edwards Lifesciences, LLCPMA supplementSep 16, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 21, 2026FDA
Edwards Lifesciences, LLCPMA supplementOct 28, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Edwards Lifesciences, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
One Edwards Way, Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records